MALVERN, PA — Ocugen, Inc. (Nasdaq: OCGN) announced it has completed enrollment for the Phase 3 liMeliGhT clinical trial evaluating OCU400, a gene therapy candidate for retinitis pigmentosa, a group ...

Clinical-stage biotech Alterity Therapeutics has appointed internationally recognised neurologist Dr Daniel O Claassen as Chief Medical Advisor as it advances its lead drug candidate ATH434 toward a ...

Multivitamins are the most common dietary supplement in the U.S. People take these pills (or gummies, indeed) for a variety of health reasons, but the science on what multivitamins may do for your ...

Tremendous activity in recent months, including receipt of Japanese marketing approval, the fifth parallel U.S. trial ...

Neuroscientists at King's College London have pinpointed a mechanism behind the increased neural connectivity observed in the very early stages of Alzheimer's disease. Published in Translational ...

DT Research will showcase the DT574 medical-grade All-in-One (AIO) computer and the WebDT Battery Fleet Manager at the HIMSS 2026 Global Health Conference and Exhibition in booth 1964, March 10-12, in ...

Positive data from EXPERTS-ALS could accelerate RT1999 towards a registration trial; RT1999 to be presented as a poster ...

Based on the clinical trial findings, Ipsen is withdrawing Tazverik across all indications, including both follicular lymphoma and epithelioid sarcoma, and is discontinuing all active tazemetostat ...

Diabetes and obesity drugs also lead to large reductions in adverse cardiovascular events, and the benefits aren’t just down ...

Medicus Pharma (NASDAQ:MDCX) said on Monday that new analysis of data from a mid-stage clinical trial of its SkinJect ...

Roquefort Therapeutics is acquiring exclusive worldwide rights to a clinical-stage tumour inhibitor for £32m in an all-paper deal and raising £8.5 million.